HIMS

At $29.32, HIMS has a market cap of $6.8B and trades at forward P/E of 22.5x based on FY2027 consensus EPS of $0.62, but FY2026 EPS is negative (-$0.13). The PEG ratio of 2.15x is elevated for a company with negative near-term earnings growth. EV/EBITDA of 88.5x is extremely expensive given the 3.5% EBITDA margin. Price-to-sales of 2.86x is moderate for the sector but unsupported by negative operating margins and deteriorating profitability. A DCF analysis from Simply Wall St suggests an intrinsic value of $61.59, implying a 46.8% discount, but this relies on optimistic cash flow growth assumptions that may not materialize given the debt burden and competitive pressures. Overall, the stock appears overvalued on near-term fundamentals but potentially undervalued on a long-term cash flow basis if execution improves, though the wide gap between current price and DCF suggests the market is pricing in significant risk.

Price at $29.32 is below the 200-day EMA ($34.09), 50-day EMA ($31.06), and 20-day SMA ($34.01), confirming a bearish trend. The EMA50/EMA200 spread is negative and declining, consistent with a death cross already in place. The stock broke below the key $30 support on July 24 and failed to hold a bounce on July 27, closing lower on July 28. The near-term trend is bearish with potential for further downside toward $27 and below.

Q1 2026 (reported May 2026): EPS of -$0.40 missed consensus of $0.026 by 1,664%, driven by restructuring and GLP-1 transition costs. Revenue also missed by 1.86%. The magnitude of the miss severely damaged management credibility.

The FDA panel recommendation on peptide compounding was the most significant catalyst, but the market's negative reaction suggests that near-term investor focus has shifted back to the company's fundamental challenges, particularly the upcoming Q2 earnings on August 10. The stock's inability to hold gains on the FDA news indicates deep skepticism about the company's ability to execute and monetize the opportunity.

VIX at 18.2 indicates moderate uncertainty, while the 10-year yield at 4.6% continues to pressure high-growth, high-beta stocks like HIMS (beta 2.34). The broad market is mixed, but HIMS's binary risk profile makes it more sensitive to company-specific events than macro moves. However, a sustained risk-off shift (VIX >25) could disproportionately exacerbate downside.

Hims & Hers remains a deeply speculative name given its leveraged balance sheet, negative earnings trajectory, and binary regulatory/competitive outlook. The FDA peptide panel win provides long-term optionality, but near-term fundamentals are deteriorating: FY2026 EPS consensus has fallen to -$0.13, revenue growth slowed to 3.8% YoY, and insider selling persists. The stock's 58% drawdown from the 52-week high reflects pervasive market skepticism. This asset is suitable only as a tactical, event-driven position with strict risk controls; it has no place in a long-term core portfolio. Investors should expect extreme daily swings (ATR ~9.5% of price) and potential for further downside if Q2 earnings on Aug 10 disappoint.